Bioventus Inc. (BVS)
7.82
0.04 (0.51%)
At close: Apr 17, 2025, 3:59 PM
0.51% (1D)
| Bid | 7 |
| Market Cap | 517.35M |
| Revenue (ttm) | 573.28M |
| Net Income (ttm) | -33.54M |
| EPS (ttm) | -0.52 |
| PE Ratio (ttm) | -15.04 |
| Forward PE | 9.18 |
| Analyst | Buy |
| Ask | 8.25 |
| Volume | 303,887 |
| Avg. Volume (20D) | 323,291 |
| Open | 7.84 |
| Previous Close | 7.78 |
| Day's Range | 7.67 - 7.87 |
| 52-Week Range | 3.90 - 14.38 |
| Beta | 0.92 |
About BVS
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones,...
Industry Medical - Devices
Sector Healthcare
IPO Date Feb 11, 2021
Employees 930
Stock Exchange NASDAQ
Ticker Symbol BVS
Website https://www.bioventus.com
Analyst Forecast
According to 3 analyst ratings, the average rating for BVS stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 91.82% from the latest price.
Stock ForecastsNext Earnings Release
Bioventus Inc. is scheduled to release its earnings on May 6, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+23.29%
Bioventus shares are trading higher after the comp...
Unlock content with
Pro Subscription
5 months ago
-16.27%
Bioventus shares are trading lower. The company reported Q3 financial results.
